ID   YLAT1_HUMAN             Reviewed;         511 AA.
AC   Q9UM01; B2RAU0; D3DS26; O95984; Q53XC1; Q86U07; Q9P2V5;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 2.
DT   10-MAY-2017, entry version 160.
DE   RecName: Full=Y+L amino acid transporter 1;
DE   AltName: Full=Monocyte amino acid permease 2;
DE            Short=MOP-2;
DE   AltName: Full=Solute carrier family 7 member 7;
DE   AltName: Full=y(+)L-type amino acid transporter 1;
DE            Short=Y+LAT1;
DE            Short=y+LAT-1;
GN   Name=SLC7A7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, TISSUE SPECIFICITY, AND
RP   VARIANT LPI ARG-334.
RX   PubMed=9829974; DOI=10.1074/jbc.273.49.32437;
RA   Torrents D., Estevez R., Pineda M., Fernandez E., Lloberas J.,
RA   Shi Y.-B., Zorzano A., Palacin M.;
RT   "Identification and characterization of a membrane protein (y+L amino
RT   acid transporter-1) that associates with 4F2hc to encode the amino
RT   acid transport activity y+L. A candidate gene for lysinuric protein
RT   intolerance.";
RL   J. Biol. Chem. 273:32437-32445(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES,
RP   AND SUBUNIT.
RC   TISSUE=Testis;
RX   PubMed=9878049; DOI=10.1093/emboj/18.1.49;
RA   Pfeiffer R., Rossier G., Spindler B., Meier C., Kuehn L.C., Verrey F.;
RT   "Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and
RT   members of the glycoprotein-associated amino acid transporter
RT   family.";
RL   EMBO J. 18:49-57(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=10080183; DOI=10.1038/6815;
RA   Borsani G., Bassi M.T., Sperandeo M.P., De Grandi A., Buoninconti A.,
RA   Riboni M., Manzoni M., Incerti B., Pepe A., Andria G., Ballabio A.,
RA   Sebastio G.;
RT   "SLC7A7, encoding a putative permease-related protein, is mutated in
RT   patients with lysinuric protein intolerance.";
RL   Nat. Genet. 21:297-301(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10737982;
RX   DOI=10.1002/(SICI)1098-1004(200004)15:4<367::AID-HUMU9>3.0.CO;2-C;
RA   Noguchi A., Shoji Y., Koizumi A., Takahashi T., Shoji Y.,
RA   Matsumori M., Kayo T., Ohata T., Wada Y., Yoshimura I., Maisawa S.,
RA   Konishi M., Takasago Y., Takada G.;
RT   "SLC7A7 genomic structure and novel variants in three Japanese
RT   lysinuric protein intolerance families.";
RL   Hum. Mutat. 15:367-372(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Takayama K., Yoshimoto M.;
RT   "Molecular and biological characterization of a novel monocyte amino
RT   acid permease, MOP-2.";
RL   Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-91.
RC   TISSUE=Kidney;
RA   Fukasawa Y., Segawa H., Endou H., Kanai Y.;
RT   "Characterization of a human system y+L amino acid transporter.";
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=B-cell, and Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=11078698;
RA   Dall'Asta V., Bussolati O., Sala R., Rotoli B.M., Sebastio G.,
RA   Sperandeo M.P., Andria G., Gazzola G.C.;
RT   "Arginine transport through system y(+)L in cultured human
RT   fibroblasts: normal phenotype of cells from LPI subjects.";
RL   Am. J. Physiol. 279:C1829-C1837(2000).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=11742806;
RA   Sala R., Rotoli B.M., Colla E., Visigalli R., Parolari A.,
RA   Bussolati O., Gazzola G.C., Dall'Asta V.;
RT   "Two-way arginine transport in human endothelial cells: TNF-alpha
RT   stimulation is restricted to system y(+).";
RL   Am. J. Physiol. 282:C134-C143(2002).
RN   [13]
RP   FUNCTION.
RX   PubMed=14603368; DOI=10.1113/eph8802647;
RA   Arancibia-Garavilla Y., Toledo F., Casanello P., Sobrevia L.;
RT   "Nitric oxide synthesis requires activity of the cationic and neutral
RT   amino acid transport system y+L in human umbilical vein endothelium.";
RL   Exp. Physiol. 88:699-710(2003).
RN   [14]
RP   FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=15280038; DOI=10.1016/j.febslet.2004.06.086;
RA   Rotoli B.M., Bussolati O., Sala R., Barilli A., Talarico E.,
RA   Gazzola G.C., Dall'Asta V.;
RT   "INFgamma stimulates arginine transport through system y+L in human
RT   monocytes.";
RL   FEBS Lett. 571:177-181(2004).
RN   [15]
RP   FUNCTION, TISSUE SPECIFICITY, AND INHIBITION.
RX   PubMed=17329401; DOI=10.1152/ajpcell.00323.2006;
RA   Rotmann A., Simon A., Martine U., Habermeier A., Closs E.I.;
RT   "Activation of classical protein kinase C decreases transport via
RT   systems y+ and y+L.";
RL   Am. J. Physiol. 292:C2259-C2268(2007).
RN   [16]
RP   TISSUE SPECIFICITY.
RX   PubMed=17197568; DOI=10.1167/iovs.06-0398;
RA   Kaneko S., Ando A., Okuda-Ashitaka E., Maeda M., Furuta K., Suzuki M.,
RA   Matsumura M., Ito S.;
RT   "Ornithine transport via cationic amino acid transporter-1 is involved
RT   in ornithine cytotoxicity in retinal pigment epithelial cells.";
RL   Invest. Ophthalmol. Vis. Sci. 48:464-471(2007).
RN   [17]
RP   VARIANT LPI ARG-334, AND CHARACTERIZATION OF VARIANT LPI ARG-334.
RX   PubMed=10080182; DOI=10.1038/6809;
RA   Torrents D., Mykkaenen J., Pineda M., Feliubadalo L., Estevez R.,
RA   de Cid R., Sanjurjo P., Zorzano A., Nunes V., Huoponen K.,
RA   Reinikainen A., Simell O., Savontaus M.-L., Aula P., Palacin M.;
RT   "Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein
RT   intolerance gene.";
RL   Nat. Genet. 21:293-296(1999).
RN   [18]
RP   VARIANT LPI ARG-386.
RX   PubMed=10631139; DOI=10.1086/302700;
RA   Sperandeo M.P., Bassi M.T., Riboni M., Parenti G., Buoninconti A.,
RA   Manzoni M., Incerti B., Larocca M.R., Di Rocco M., Strisciuglio P.,
RA   Dianzani I., Parini R., Candito M., Endo F., Ballabio A., Andria G.,
RA   Sebastio G., Borsani G.;
RT   "Structure of the SLC7A7 gene and mutational analysis of patients
RT   affected by lysinuric protein intolerance.";
RL   Am. J. Hum. Genet. 66:92-99(2000).
RN   [19]
RP   VARIANTS LPI VAL-54 AND ASP-338, AND CHARACTERIZATION OF VARIANTS LPI
RP   VAL-54 AND ARG-334.
RX   PubMed=10655553; DOI=10.1093/hmg/9.3.431;
RA   Mykkaenen J., Torrents D., Pineda M., Camps M., Yoldi M.E.,
RA   Horelli-Kuitunen N., Huoponen K., Heinonen M., Oksanen J., Simell O.,
RA   Savontaus M.-L., Zorzano A., Palacin M., Aula P.;
RT   "Functional analysis of novel mutations in y+LAT-1 amino acid
RT   transporter gene causing lysinuric protein intolerance (LPI).";
RL   Hum. Mol. Genet. 9:431-438(2000).
RN   [20]
RP   VARIANTS LPI PHE-238 AND PRO-489.
RX   PubMed=12402335; DOI=10.1002/humu.10140;
RA   Shoji Y., Noguchi A., Shoji Y., Matsumori M., Takasago Y.,
RA   Takayanagi M., Yoshida Y., Ihara K., Hara T., Yamaguchi S.,
RA   Yoshino M., Kaji M., Yamamoto S., Nakai A., Koizumi A., Hokezu Y.,
RA   Nagamatsu K., Mikami H., Kitajima I., Takada G.;
RT   "Five novel SLC7A7 variants and y+L gene-expression pattern in
RT   cultured lymphoblasts from Japanese patients with lysinuric protein
RT   intolerance.";
RL   Hum. Mutat. 20:375-381(2002).
RN   [21]
RP   CHARACTERIZATION OF VARIANTS LPI LEU-36 DEL AND LEU-152, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15756301; DOI=10.1038/sj.ejhg.5201376;
RA   Sperandeo M.P., Paladino S., Maiuri L., Maroupulos G.D., Zurzolo C.,
RA   Taglialatela M., Andria G., Sebastio G.;
RT   "A y(+)LAT-1 mutant protein interferes with y(+)LAT-2 activity:
RT   implications for the molecular pathogenesis of lysinuric protein
RT   intolerance.";
RL   Eur. J. Hum. Genet. 13:628-634(2005).
RN   [22]
RP   VARIANTS LPI LYS-50; ILE-188 AND MET-333, AND CHARACTERIZATION OF
RP   VARIANTS LPI LYS-50; ILE-188 AND ARG-386.
RX   PubMed=15776427; DOI=10.1002/humu.9323;
RA   Sperandeo M.P., Annunziata P., Ammendola V., Fiorito V., Pepe A.,
RA   Soldovieri M.V., Taglialatela M., Andria G., Sebastio G.;
RT   "Lysinuric protein intolerance: identification and functional analysis
RT   of mutations of the SLC7A7 gene.";
RL   Hum. Mutat. 25:410-410(2005).
RN   [23]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-413.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [24]
RP   VARIANTS LPI ILE-5; GLU-36 DEL; LYS-50; LEU-53; VAL-54; PRO-124;
RP   PRO-140; LEU-152; ILE-188; GLU-191; PHE-238; ASP-251; PRO-261;
RP   MET-333; ARG-334; ASP-338; TYR-365; ARG-386 AND PRO-489.
RX   PubMed=17764084; DOI=10.1002/humu.20589;
RA   Sperandeo M.P., Andria G., Sebastio G.;
RT   "Lysinuric protein intolerance: update and extended mutation analysis
RT   of the SLC7A7 gene.";
RL   Hum. Mutat. 29:14-21(2008).
CC   -!- FUNCTION: Involved in the sodium-independent uptake of dibasic
CC       amino acids and sodium-dependent uptake of some neutral amino
CC       acids. Requires coexpression with SLC3A2/4F2hc to mediate the
CC       uptake of arginine, leucine and glutamine. Plays a role in nitric
CC       oxide synthesis in human umbilical vein endothelial cells (HUVECs)
CC       via transport of L-arginine. Involved in the transport of L-
CC       arginine in monocytes. {ECO:0000269|PubMed:14603368,
CC       ECO:0000269|PubMed:15280038, ECO:0000269|PubMed:17329401,
CC       ECO:0000269|PubMed:9829974, ECO:0000269|PubMed:9878049}.
CC   -!- ENZYME REGULATION: Arginine transport is inhibited by protein
CC       kinase C (PKC) and treatment with phorbol-12-myristate-13-acetate
CC       (PMA).
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=31.7 uM for L-leucine (in the presence of 0.1 M NaCl)
CC         {ECO:0000269|PubMed:9878049};
CC         KM=16.2 uM for L-leucine (in the presence of 0.1 M LiCl)
CC         {ECO:0000269|PubMed:9878049};
CC   -!- SUBUNIT: Disulfide-linked heterodimer with the amino acid
CC       transport protein SLC3A2/4F2hc. {ECO:0000269|PubMed:9829974,
CC       ECO:0000269|PubMed:9878049}.
CC   -!- SUBCELLULAR LOCATION: Basolateral cell membrane
CC       {ECO:0000269|PubMed:15756301}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:15756301}.
CC   -!- TISSUE SPECIFICITY: Highest expression in kidney and peripheral
CC       blood leukocytes. Weaker expression is observed in lung, heart,
CC       placenta, spleen, testis and small intestine. Expressed in normal
CC       fibroblasts and those from LPI patients. Also expressed in HUVECs,
CC       monocytes, retinal pigment epithelial cells, and various carcinoma
CC       cell lines, with highest expression in a colon-carcinoma cell
CC       line. {ECO:0000269|PubMed:10080183, ECO:0000269|PubMed:11078698,
CC       ECO:0000269|PubMed:11742806, ECO:0000269|PubMed:15280038,
CC       ECO:0000269|PubMed:17197568, ECO:0000269|PubMed:17329401,
CC       ECO:0000269|PubMed:9829974}.
CC   -!- INDUCTION: Expression is stimulated and enhanced by IFNG/IFN-
CC       gamma. {ECO:0000269|PubMed:15280038}.
CC   -!- DISEASE: Lysinuric protein intolerance (LPI) [MIM:222700]: A
CC       metabolic disorder characterized by increased renal excretion of
CC       cationic amino acid (CAA), reduced CAA absorption from intestine,
CC       and orotic aciduria. On a normal diet, LPI patients present poor
CC       feeding, vomiting, diarrhea, episodes of hyperammoniaemic coma and
CC       growth retardation. Hepatosplenomegaly, osteoporosis and a life-
CC       threatening pulmonary involvement (alveolar proteinosis) are also
CC       seen. Biochemically LPI is characterized by defective transport of
CC       dibasic amino acids at the basolateral membrane of epithelial
CC       cells in kidney and intestine. {ECO:0000269|PubMed:10080182,
CC       ECO:0000269|PubMed:10631139, ECO:0000269|PubMed:10655553,
CC       ECO:0000269|PubMed:12402335, ECO:0000269|PubMed:15756301,
CC       ECO:0000269|PubMed:15776427, ECO:0000269|PubMed:17764084,
CC       ECO:0000269|PubMed:9829974}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the amino acid-polyamine-organocation (APC)
CC       superfamily. L-type amino acid transporter (LAT) (TC 2.A.3.8)
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA95120.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAD62619.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF092032; AAC83706.1; -; mRNA.
DR   EMBL; AJ130718; CAA10198.1; -; mRNA.
DR   EMBL; Y18474; CAB40136.1; -; mRNA.
DR   EMBL; AB031537; BAA95120.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AB011263; BAB11849.1; -; mRNA.
DR   EMBL; AB020532; BAA87623.1; -; mRNA.
DR   EMBL; BX161519; CAD61952.1; -; mRNA.
DR   EMBL; BX248291; CAD62619.1; ALT_INIT; mRNA.
DR   EMBL; AK314351; BAG36987.1; -; mRNA.
DR   EMBL; CH471078; EAW66245.1; -; Genomic_DNA.
DR   EMBL; CH471078; EAW66246.1; -; Genomic_DNA.
DR   EMBL; CH471078; EAW66247.1; -; Genomic_DNA.
DR   EMBL; CH471078; EAW66248.1; -; Genomic_DNA.
DR   EMBL; BC003062; AAH03062.1; -; mRNA.
DR   EMBL; BC010107; AAH10107.1; -; mRNA.
DR   CCDS; CCDS9574.1; -.
DR   RefSeq; NP_001119577.1; NM_001126105.2.
DR   RefSeq; NP_001119578.1; NM_001126106.2.
DR   RefSeq; XP_006720365.1; XM_006720302.1.
DR   RefSeq; XP_011535600.1; XM_011537298.2.
DR   RefSeq; XP_011535601.1; XM_011537299.1.
DR   UniGene; Hs.513147; -.
DR   UniGene; Hs.732349; -.
DR   ProteinModelPortal; Q9UM01; -.
DR   BioGrid; 114518; 2.
DR   IntAct; Q9UM01; 1.
DR   STRING; 9606.ENSP00000285850; -.
DR   DrugBank; DB08838; Agmatine.
DR   TCDB; 2.A.3.8.22; the amino acid-polyamine-organocation (apc) family.
DR   iPTMnet; Q9UM01; -.
DR   PhosphoSitePlus; Q9UM01; -.
DR   BioMuta; SLC7A7; -.
DR   DMDM; 12643378; -.
DR   MaxQB; Q9UM01; -.
DR   PaxDb; Q9UM01; -.
DR   PeptideAtlas; Q9UM01; -.
DR   PRIDE; Q9UM01; -.
DR   DNASU; 9056; -.
DR   Ensembl; ENST00000285850; ENSP00000285850; ENSG00000155465.
DR   Ensembl; ENST00000397528; ENSP00000380662; ENSG00000155465.
DR   Ensembl; ENST00000397529; ENSP00000380663; ENSG00000155465.
DR   Ensembl; ENST00000397532; ENSP00000380666; ENSG00000155465.
DR   Ensembl; ENST00000555702; ENSP00000451881; ENSG00000155465.
DR   GeneID; 9056; -.
DR   KEGG; hsa:9056; -.
DR   UCSC; uc001wgr.5; human.
DR   CTD; 9056; -.
DR   DisGeNET; 9056; -.
DR   GeneCards; SLC7A7; -.
DR   GeneReviews; SLC7A7; -.
DR   HGNC; HGNC:11065; SLC7A7.
DR   HPA; HPA036227; -.
DR   MalaCards; SLC7A7; -.
DR   MIM; 222700; phenotype.
DR   MIM; 603593; gene.
DR   neXtProt; NX_Q9UM01; -.
DR   OpenTargets; ENSG00000155465; -.
DR   Orphanet; 470; Lysinuric protein intolerance.
DR   PharmGKB; PA35925; -.
DR   eggNOG; KOG1287; Eukaryota.
DR   eggNOG; COG0531; LUCA.
DR   GeneTree; ENSGT00760000119037; -.
DR   HOVERGEN; HBG000476; -.
DR   InParanoid; Q9UM01; -.
DR   KO; K13867; -.
DR   OMA; DFLCMIH; -.
DR   OrthoDB; EOG091G07EM; -.
DR   PhylomeDB; Q9UM01; -.
DR   TreeFam; TF313355; -.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-352230; Amino acid transport across the plasma membrane.
DR   SABIO-RK; Q9UM01; -.
DR   ChiTaRS; SLC7A7; human.
DR   GeneWiki; SLC7A7; -.
DR   GenomeRNAi; 9056; -.
DR   PRO; PR:Q9UM01; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000155465; -.
DR   CleanEx; HS_SLC7A7; -.
DR   ExpressionAtlas; Q9UM01; baseline and differential.
DR   Genevisible; Q9UM01; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0015297; F:antiporter activity; IBA:GO_Central.
DR   GO; GO:0015174; F:basic amino acid transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015179; F:L-amino acid transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0006865; P:amino acid transport; TAS:Reactome.
DR   GO; GO:0006520; P:cellular amino acid metabolic process; TAS:ProtInc.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0006461; P:protein complex assembly; TAS:ProtInc.
DR   GO; GO:0000821; P:regulation of arginine metabolic process; IBA:GO_Central.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   InterPro; IPR002293; AA/rel_permease1.
DR   Pfam; PF13520; AA_permease_2; 1.
DR   PIRSF; PIRSF006060; AA_transporter; 1.
PE   1: Evidence at protein level;
KW   Amino-acid transport; Cell membrane; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Membrane;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1    511       Y+L amino acid transporter 1.
FT                                /FTId=PRO_0000054281.
FT   TRANSMEM     37     57       Helical. {ECO:0000255}.
FT   TRANSMEM     69     89       Helical. {ECO:0000255}.
FT   TRANSMEM    107    127       Helical. {ECO:0000255}.
FT   TRANSMEM    133    153       Helical. {ECO:0000255}.
FT   TRANSMEM    160    180       Helical. {ECO:0000255}.
FT   TRANSMEM    186    206       Helical. {ECO:0000255}.
FT   TRANSMEM    222    242       Helical. {ECO:0000255}.
FT   TRANSMEM    259    279       Helical. {ECO:0000255}.
FT   TRANSMEM    304    324       Helical. {ECO:0000255}.
FT   TRANSMEM    383    403       Helical. {ECO:0000255}.
FT   TRANSMEM    416    436       Helical. {ECO:0000255}.
FT   TRANSMEM    441    461       Helical. {ECO:0000255}.
FT   MOD_RES      18     18       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Z1K8}.
FT   MOD_RES      25     25       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Z1K8}.
FT   CARBOHYD    325    325       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VARIANT       5      5       T -> I (in LPI; dbSNP:rs386833792).
FT                                {ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_039092.
FT   VARIANT      36     36       Missing (in LPI; failed to induce
FT                                cationic amino acid transport activity).
FT                                {ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_039093.
FT   VARIANT      50     50       M -> K (in LPI; failed to induce cationic
FT                                amino acid transport activity;
FT                                dbSNP:rs386833811).
FT                                {ECO:0000269|PubMed:15776427,
FT                                ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_030595.
FT   VARIANT      53     53       S -> L (in LPI; dbSNP:rs386833793).
FT                                {ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_039094.
FT   VARIANT      54     54       G -> V (in LPI; failed to induce cationic
FT                                amino acid transport activity;
FT                                dbSNP:rs121908677).
FT                                {ECO:0000269|PubMed:10655553,
FT                                ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_010261.
FT   VARIANT      91     91       A -> V (in dbSNP:rs11568438).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_039095.
FT   VARIANT     124    124       L -> P (in LPI; dbSNP:rs386833814).
FT                                {ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_039096.
FT   VARIANT     140    140       A -> P (in LPI; dbSNP:rs386833815).
FT                                {ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_039097.
FT   VARIANT     152    152       F -> L (in LPI; moderately reduced
FT                                cationic amino acid transport activity;
FT                                dbSNP:rs386833816).
FT                                {ECO:0000269|PubMed:15756301,
FT                                ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_039098.
FT   VARIANT     159    159       R -> C (in dbSNP:rs11568437).
FT                                /FTId=VAR_039099.
FT   VARIANT     188    188       T -> I (in LPI; failed to induce cationic
FT                                amino acid transport activity;
FT                                dbSNP:rs386833819).
FT                                {ECO:0000269|PubMed:15776427,
FT                                ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_030596.
FT   VARIANT     191    191       K -> E (in LPI; dbSNP:rs386833820).
FT                                {ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_039100.
FT   VARIANT     238    238       S -> F (in LPI; dbSNP:rs386833823).
FT                                {ECO:0000269|PubMed:12402335,
FT                                ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_030597.
FT   VARIANT     251    251       E -> D (in LPI; dbSNP:rs386833824).
FT                                {ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_039101.
FT   VARIANT     261    261       L -> P (in LPI; dbSNP:rs386833825).
FT                                {ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_039102.
FT   VARIANT     333    333       R -> M (in LPI; dbSNP:rs386833829).
FT                                {ECO:0000269|PubMed:15776427,
FT                                ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_030598.
FT   VARIANT     334    334       L -> R (in LPI; failed to induce cationic
FT                                amino acid transport activity;
FT                                dbSNP:rs72552272).
FT                                {ECO:0000269|PubMed:10080182,
FT                                ECO:0000269|PubMed:10655553,
FT                                ECO:0000269|PubMed:17764084,
FT                                ECO:0000269|PubMed:9829974}.
FT                                /FTId=VAR_010262.
FT   VARIANT     338    338       G -> D (in LPI; dbSNP:rs386833795).
FT                                {ECO:0000269|PubMed:10655553,
FT                                ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_010999.
FT   VARIANT     365    365       N -> Y (in LPI; dbSNP:rs386833797).
FT                                {ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_039103.
FT   VARIANT     386    386       S -> R (in LPI; failed to induce cationic
FT                                amino acid transport activity;
FT                                dbSNP:rs386833799).
FT                                {ECO:0000269|PubMed:10631139,
FT                                ECO:0000269|PubMed:15776427,
FT                                ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_011000.
FT   VARIANT     413    413       P -> S (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036609.
FT   VARIANT     489    489       S -> P (in LPI; dbSNP:rs386833810).
FT                                {ECO:0000269|PubMed:12402335,
FT                                ECO:0000269|PubMed:17764084}.
FT                                /FTId=VAR_030599.
SQ   SEQUENCE   511 AA;  55991 MW;  A71D677B6B075894 CRC64;
     MVDSTEYEVA SQPEVETSPL GDGASPGPEQ VKLKKEISLL NGVCLIVGNM IGSGIFVSPK
     GVLIYSASFG LSLVIWAVGG LFSVFGALCY AELGTTIKKS GASYAYILEA FGGFLAFIRL
     WTSLLIIEPT SQAIIAITFA NYMVQPLFPS CFAPYAASRL LAAACICLLT FINCAYVKWG
     TLVQDIFTYA KVLALIAVIV AGIVRLGQGA STHFENSFEG SSFAVGDIAL ALYSALFSYS
     GWDTLNYVTE EIKNPERNLP LSIGISMPIV TIIYILTNVA YYTVLDMRDI LASDAVAVTF
     ADQIFGIFNW IIPLSVALSC FGGLNASIVA ASRLFFVGSR EGHLPDAICM IHVERFTPVP
     SLLFNGIMAL IYLCVEDIFQ LINYYSFSYW FFVGLSIVGQ LYLRWKEPDR PRPLKLSVFF
     PIVFCLCTIF LVAVPLYSDT INSLIGIAIA LSGLPFYFLI IRVPEHKRPL YLRRIVGSAT
     RYLQVLCMSV AAEMDLEDGG EMPKQRDPKS N
//
